<DOC>
	<DOCNO>NCT00542763</DOCNO>
	<brief_summary>Primary Sjogren 's syndrome ( pSS ) autoimmune disorder characterize keratoconjunctivitis sicca xerostomia . In addition , various extraglandular manifestation may develop . Several immunomodulating agent attempt treatment pSS without achieve satisfactory result . Currently , approve systemic treatment pSS . Mycophenolic acid ( MPA ) selective inhibitor inosine-monophosphate-dehydrogenase lead inhibition de novo pathway nucleotide synthesis . The antiproliferative effect MPA mainly affect activated T- B-lymphocytes proliferation cell critically dependent de novo purine synthesis compare eukaryotic cell . Since lymphocyte suggest play pivotal role inflammation immunopathogenesis pSS , mycophenolate-sodium might promise agent treatment pSS . We perform single-centre , open-label pilot trial Mycophenolate sodium pSS .</brief_summary>
	<brief_title>Mycophenolate Sodium Treatment Patients With Primary Sjogren 's Syndrome</brief_title>
	<detailed_description>Mycophenolic acid contain compound mycophenolate mofetil enteric coat mycophenolate sodium immunosuppressive drug approve prevention transplant rejection . Mycophenolate mofetil ( MMF ) effective treatment systemic lupus erythematosus autoimmune disease . MMF use maintenance therapy treatment rituximab ( anti-CD20 antibody ) pSS patient . We report case successful treatment MMF pSS vasculitis . The recent observation immunosuppressive effect MPA autoimmune disease lead u evaluate efficacy safety MPA treatment patient pSS refractory immunosuppressive agent . The observation period 6 month . At baseline , 3 , 6 month examine clinical status include glandular function test well different laboratory parameter associate pSS . In addition subjective parameter determine basis different questionnaire .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Diagnosis primary Sjogren ' Syndrome base AmericanEuropean Consensus criterion Erythrocyte sedimentation rate &gt; 25mm/h hypergammaglobulinemia ( &gt; 1500 mg/dl ) Presence antiSSA /or SSB antibodies / rheumatoid factor Requirement artificial teardrop due symptomatic sicca syndrome Inadequate response intolerance prior treatment hydroxychloroquine / azathioprine Adequate contraception female childbearing potential Age 18 75 year Secondary Sjogren 's syndrome History cancer , severe infection uncontrolled disease Treatment concomitant disease modify antirheumatic drug within least 8 week baseline evaluation Prednisolone dose &gt; 5mg/d change prednisolone dose within least 4 week baseline Use secretagogues ( e.g . pilocarpine , cevimeline ) medication potentially diminish exocrine gland function ( e.g . tricyclic antidepressant , anticholinergic drug ) Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>Sjogren 's syndrome</keyword>
	<keyword>Mycophenolate sodium</keyword>
</DOC>